A Systematic Investigation of Phonetic Complexity Effects on Articulatory Motor Performance in Progressive Dysarthria
Understanding Communication and Cognitive Impairments in Neurodegenerative Disorders
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Kansas
-
Fairway, Kansas, United States, 66205
- University of Kansas Medical Center
-
-
Missouri
-
Columbia, Missouri, United States, 65211
- University of Missouri-Columbia
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- May or may not have a neurological impairment.
- Age range of 19-90 years.
- Male or female.
- Provide written consent before any study specific procedures are performed.
- Have ability to comply with basic instructions.
- Monolingual English speaker.
- Have ability to partake in a 90 minute data collection.
Exclusion Criteria:
- Any speech, language, cognition, or hearing impairment prior to diagnosis of a neurodegenerative disease.
- Anyone not appropriate for study participation, as deemed by the principal investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: Phonetic complexity effects
Conduct a comprehensive kinematic assessment using state-of-the art 3D speech tracking technology on individuals with ALS and PD as well as healthy talkers to identify articulatory motor disturbances as a function of phonetic complexity and dysarthria severity.
Phonetic complexity will be experimentally manipulated using the consonant and vowel complexity classification system proposed by Kent (1992) that takes into account the underlying articulatory motor adjustments required to produce various speech sounds.
|
Use of 3D electromagnetic articulography to examine phonetic complexity effects of single word stimuli at the articulatory kinematic level in talkers each with preclinical, mild, and moderate dysarthria, relative to healthy controls.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Peak movement speed
Time Frame: Up to 3 months after enrollment
|
Peak speed (millimeters/second) for each articulatory marker is the maximum value of the first-order derivative of each marker's Euclidean distance time-history.
|
Up to 3 months after enrollment
|
|
Range of movement
Time Frame: Up to 3 months after enrollment
|
The convex hull represents the smallest convex set containing all the points in the 3D motion path.
|
Up to 3 months after enrollment
|
|
Duration
Time Frame: Up to 3 months after enrollment
|
Word duration (seconds) is the time between onset and offset of movement for each word.
|
Up to 3 months after enrollment
|
|
Spatiotemporal movement variability (STI)
Time Frame: Up to 3 months after enrollment
|
STI is the most widely used metric to capture movement pattern variability during speech.
To determine STI, the pattern of articulatory movements and the variability of that pattern over several repetitions of an utterance are examined.
|
Up to 3 months after enrollment
|
|
Inter-articulator coordination
Time Frame: Up to 3 months after enrollment
|
Spatiotemporal coupling relations between articulators will be derived from vertical movements of the articulators using a covariance measure.
|
Up to 3 months after enrollment
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Mili Kuruvilla-Dugdale, PhD, University of Missouri-Columbia
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Metabolic Diseases
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurologic Manifestations
- Neurobehavioral Manifestations
- Neuromuscular Diseases
- Parkinsonian Disorders
- Basal Ganglia Diseases
- Movement Disorders
- Synucleinopathies
- Neurodegenerative Diseases
- Spinal Cord Diseases
- TDP-43 Proteinopathies
- Proteostasis Deficiencies
- Language Disorders
- Communication Disorders
- Speech Disorders
- Articulation Disorders
- Parkinson Disease
- Motor Neuron Disease
- Amyotrophic Lateral Sclerosis
- Dysarthria
Other Study ID Numbers
Other Study ID Numbers
- 1209643
- 1R15DC016383-01 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- Study Protocol
- Statistical Analysis Plan (SAP)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.